PLK1 and prostate cancer: What’s more, BI2536, an inhibitor of serine/threonine protein kinase Polo-like Kinase 1 (PLK1), has been reported to induce necroptosis in androgen-insensitive prostate cancer cells (LNCaP-AI) to overcome castration-resistance (153).